At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 591 enrolled
Drug / intervention
Dulaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
In Brief
A Phase 3 clinical trial evaluating Dulaglutide and Oral antihyperglycemics for Diabetes Mellitus and 6 related conditions. Completed, enrolled 591 participants across 44 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Hypoglycemic Agents, Type 2 Diabetes Mellitus (T2DM)
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartApr 2021
Primary CompletionOct 2022
Study CompletionApr 2023
TodayJul 2026
First PostedMar 22, 2021
Enrollment StartApr 13, 2021
Primary CompletionOct 1, 2022
Study CompletionApr 26, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.3 years ago
Interventions
Dulaglutidedrug
Administered SC
Oral antihyperglycemicsdrug
Administered orally